The Three Pillars of Professional Screening
Pillar 1: Quality
Quality metrics measure the structural health and competitive advantage of the business. Key quality indicators include:
- Return on Equity (ROE): Net profit as a percentage of shareholders' equity. Above 15% suggests strong profitability relative to the capital employed.
- Operating Margin: Measures pricing power and operational efficiency. Compare to sector average — a margin significantly above the sector average suggests a genuine competitive advantage.
- Free Cash Flow Conversion: What percentage of operating profit converts to actual cash? High conversion (above 80%) indicates quality earnings; low conversion may suggest accounting practices inflating reported profits.
- Debt/Equity Ratio: Financial leverage. Below 1.0 is broadly conservative; above 2.0 warrants careful analysis of debt terms and cash flow coverage.
- Interest Coverage: Operating profit divided by interest expense. Above 5x is healthy; below 2x is a potential stress indicator.
Pillar 2: Value
Value metrics measure whether you are paying a reasonable price for the quality you are buying. The classic value trap is buying a low-quality business cheaply; the better opportunity is buying a high-quality business at a fair or reasonable price.
- P/E Ratio: Price divided by earnings per share. Always compare against the company's own historical P/E range and the sector average, not an absolute threshold.
- EV/EBITDA: Enterprise Value divided by earnings before interest, tax, depreciation, and amortisation. More comparable across companies with different capital structures than P/E. Below 10x is broadly attractive for most FTSE 100 sectors.
- Price/Free Cash Flow: More conservative than P/E because it uses actual cash generation rather than accounting earnings. Below 15x is generally attractive.
- Price/Book: Useful for financials (banks, insurance) but less so for IP-heavy businesses. Below 1.5x is attractive for most sectors; banks below 1.0x price-to-book are often statistically cheap.
Pillar 3: Momentum
Academic research consistently shows that stocks with positive price momentum continue to outperform in the medium term (3-12 months). Combining momentum with quality and value significantly improves the signal-to-noise ratio.
- 12-month price momentum: Stocks in the top 30% of 12-month price performance within their sector tend to continue outperforming. This reflects genuine fundamental momentum (improving earnings, analyst upgrades) rather than pure speculation.
- Earnings revision momentum: When analysts revise earnings estimates upward, it typically precedes further upgrades. Stocks with consistent positive estimate revisions are in a fundamentally improving trend.
- RSI (Relative Strength Index): A technical momentum indicator. RSI in the 50-70 range suggests positive but not overbought momentum — the sweet spot for momentum-driven entry.
FTSE 100 Sector Breakdown
Understanding the FTSE 100's sector composition is essential for contextualising any screen results. The index is heavily concentrated in a few sectors:
| Sector | Approx. Weight | Key Names | Screening Notes |
|---|
| Financials | ~20% | HSBC, Lloyds, Barclays, Aviva | Use ROE and P/Book; different metrics from industrials |
| Energy | ~15% | Shell, BP | Adjust for commodity cycle; use through-cycle earnings |
| Healthcare | ~12% | AstraZeneca, GSK | Focus on pipeline, margins; high R&D distorts near-term P/E |
| Consumer Staples | ~12% | Unilever, Diageo, Reckitt | Stable margins; focus on organic revenue growth |
| Mining | ~10% | Rio Tinto, BHP, Glencore, Anglo | Commodity cycle sensitivity; use EV/EBITDA at mid-cycle |
| Industrials | ~8% | BAE Systems, Rolls-Royce, Experian | Order books, margins, FCF conversion |
| Consumer Discret. | ~5% | Next, JD Sports, B&M | Cyclical; screen at trough rather than peak multiples |
| Other | ~18% | Various | Apply sector-specific criteria |
Why Each Sector Needs Different Screening Criteria
One of the most common mistakes retail investors make is applying identical screening thresholds across all sectors. The metrics that indicate quality in a pharmaceutical company are fundamentally different from those that indicate quality in a bank or a retailer.
Banks: ROE and Price/Book are the primary metrics. Banks use leverage to generate returns, so their operating margins are not comparable to industrial companies. A bank with 12-15% ROE and 0.8x Price/Book is cheap; the same numbers mean something entirely different for a manufacturer.
Mining companies: Commodity companies' earnings are highly cyclical. Screening for low P/E at the peak of a commodity cycle will give you a misleading signal — those earnings are about to normalise downward. Professional analysts use "mid-cycle" or "normalised" earnings estimates rather than trailing reported earnings.
Pharmaceutical companies: High P/E ratios reflect long-duration earnings streams from patented drugs. A pharma on 20x P/E with a rich pipeline, high margins, and strong FCF conversion may be far better value than a retailer on 10x P/E with thin margins and no pricing power.
The Quality-Value Sweet Spot
The highest-probability investment opportunities in the FTSE 100 consistently come from companies that are simultaneously high-quality and reasonably valued. The combination is rare because the market generally recognises quality and prices it accordingly. But it occurs during:
- Sector rotation periods when capital flows away from a sector temporarily, depressing valuations of good companies alongside bad ones
- Company-specific controversies that are temporary (a profit warning from a one-off cost, a management change) rather than structural
- Market-wide selloffs that hit all stocks indiscriminately, including those with no fundamental deterioration
- Post-results days when the market over-reacts to short-term guidance disappointments in companies with strong long-term fundamentals
Finding these opportunities requires a systematic screen that flags quality companies (Pillar 1) trading at below-average valuations (Pillar 2) with no deteriorating momentum signal that would suggest the cheapness is justified (Pillar 3).